Primary graft failure (pGF) is a frequent complication following cord blood transplantation (CBT). For those patients who will not experience autologous recovery, salvage transplantation should be performed as early as possible. However, standardized treatment protocols for pGF, such as the optimal stem cell source, preparative regimen and the ideal time for salvage transplantation, have yet to be determined. Therefore, we analyzed 17 hematologic malignancy patients who received unmanipulated haploidentical peripheral blood (PB) and BM transplantation with reduced-intensity conditioning (RIC) as a salvage therapy for pGF after CBT. The median interval between the two transplantations was 38 days. The RIC regimen for salvage transplantation consisted of fludarabine, antithymocyte globulin, CY and low-dose TBI. The neutrophil and plt engraftments were achieved in 14 (82.4%) and 13 (76.4%) patients, respectively. The cumulative incidences of grades II-IV and grades III-IV aGVHD were 35.3% and 17.6%, respectively. The cumulative incidence of chronic GVHD was 29.4%. After a median follow-up of 43 months, 10 of 17 patients remained alive in CR. The cumulative incidence of TRM at 180 days was 29.4%. The probability of 3-year OS and leukemia-free survival was 57.5%. Our results show that unmanipulated haploidentical PB and BM transplantation under a RIC regimen is an effective treatment for pGF after CBT.
INTRODUCTION
Unrelated donor cord blood transplantation (CBT) is an alternative to matched-unrelated or mismatched-related peripheral blood (PB) or BMT and has emerged as a widely accepted treatment for a wide variety of hematologic malignancies. 1 Primary graft failure (pGF) is a potentially lethal complication of CBT. Retrospective data indicate that the overall frequency of graft failure (GF) might be as high as 20% after CBT. 2, 3 The mechanisms of GF after CBT remain unclear. With the exception of inadequate cord blood stem cell doses or defects in the host BM microenvironment, the immune response of the recipient is thought to serve as a major mechanism of GF, it may be induced by residual host immunocompetent cells, hemophagocytic syndrome, 4 septicemia 5 and various viral infections, such as parvovirus, CMV and human herpesvirus 6. In addition, the use of non-myeloablative or reduced-intensity conditioning (RIC) regimens, T-cell depletion from the graft and the presence of donor-specific HLA Abs also increase the risk of GF.
Without autologous recovery, pGF following CBT is often associated with considerable morbidity and mortality for patients who do not receive salvage transplantation. 6 Salvage transplantation is urgent and necessary given the precarious condition of patients owing to prolonged marrow aplasia after the initial transplantation. A second transplantation from an immediately available donor is the optimal therapeutic option. In recent years, the increased permissiveness of HLA Ag-disparities and the advances in HLA typing have improved GVHD prevention and supportive care outcomes using haploidentical donors. [7] [8] [9] [10] For patients who lack conventional donors, haploidentical hematopoietic SCT (HSCT) is a viable treatment option.
In this study, we report the details of 17 patients with hematologic malignancies who suffered from pGF after CBT. We chose haploidentical donors without in vitro T-cell depletion as the salvage stem cell source because of the rapid donor availability and engraftment to reduce the duration of post-transplant neutropenia.
PATIENTS AND METHODS Patients
This retrospective analysis included 17 consecutive patients with hematologic malignancies who suffered from pGF following CBT. All of the patients received salvage transplantation from a haploidentical related donor between February 2006 and February 2013 in Anhui Provincial Hospital. The diagnoses and clinical characteristics of the first transplantation procedure are presented in Table 1 . At the time of the first transplantation, the median age of the patients was 11 years (range, 4-48 years), and the median body wt was 34 kg (range, 15-76 kg). HLA compatibility was determined by low-resolution DNA techniques for HLA-A and B loci and high-resolution molecular techniques for HLA-DRB1. Patients and their donors were haploidentical. All patients met the following criteria: (1) voluntary participation in salvage transplantation; informed consent obtained from patients or their guardians and donors; (2) engraftment not achieved after a prior CBT and no relapse of the primary disease before the second HSCT; (3) absence of active infection and severe organ function failure, with performance status ⩾ 70%; and (4) salvage transplantation performed within 60 days of the first CBT. This study was approved by the Institutional Review Board of Anhui Provincial Hospital in China.
Preparative regimen for salvage transplantation
For the second transplantation, RIC regimens were administered to accommodate the short transplantation interval. The regimens consisted of fludarabine (30 mg/m 2 /day i.v.) on days − 6 to − 3, rabbit antithymocyte globulin (Sangstat-Genzyme, Lyon, France, 2.5 mg/kg/day i.v.) on days − 5 to − 3, CY (50 mg/kg/day i.v.) on day − 2, and a single dose of 3 Gy TBI on day − 1.
Stem cell harvesting
Donors were given G-CSF (5-10 μg/kg/day; Filgrastim, Kirin, Tokyo, Japan) for five consecutive days before PBSCs harvesting. PBSCs were collected using an automated continuous flow blood cell separator (CS3000; Baxter, Deerfield, IL, USA). Two days later, BM grafts were harvested to achieve a target volume of 10-12 ml/kg donor wt. The plasma and RBCs were excluded using sedimentation with Hespan for the ABO minor-and majormismatched donors, respectively. The median dose of infused total nucleated cells was 8 /kg). The median interval from the first CBT to salvage transplantation was 38 days (range, 32-59 days). These data are shown in Table 2 .
GVHD prophylaxis and management
All patients received a combination of CsA (Novartis, Stein, Switzerland) and MMF (Roche, Basel, Switzerland) as GVHD prophylaxis. i.v. CsA was initially administered at 3 mg/kg/day i.v. from day − 1 with target trough levels of 200-400 ng/ml at a minimum of one month, and was switched to an oral formulation as soon as oral intake could be tolerated. MMF (20-30 mg/kg/day, p.o. 3-4 times/day) was administered on day +1 until day +28 or until hematopoietic reconstitution was achieved. The tapering of CsA and MMF was based on the presence or absence of GVHD, infectious disease and the risk of relapse.
Supportive care
Patients were hospitalized in single rooms ventilated with HEPA-filtered systems. G-CSF (5 μg/kg/day) was administered i.v. from day +6 until neutrophil recovery. Blood products were irradiated with 2500 cGy before infusion. All patients received oral antibiotics, azoles (itraconazole or voriconazole) and i.v. acyclovir as infection prophylaxis. CMV and EBV were regularly monitored by DNA quantitation using PCR analysis in the PB. Ganciclovir or foscarnet was used as a preemptive CMV therapy.
Chimerism analysis and definitions
Neutrophil engraftment was defined as the first of three consecutive days with an ANC ⩾ 0.5 × 10 9 /L, and plt engraftment was defined as the first day that the plt count maintained ⩾ 20 × 10 9 /L for seven consecutive days without transfusion support. Chimerism was assessed using PCR analysis of STR sequences at various time points of CBT and the salvage transplantation, including days +7, +14, +21 and +28 after CBT; days +30, +60, +90 and +180 after salvage transplantation; and years +1, +2 and +3 after salvage transplantation. Complete chimerism was defined if only donor cells were detected, whereas mixed chimerism was defined as the detection of 5-95% donor cells. pGF was defined as peripheral cytopenia and marrow hypoplasia occurring after day 28 without the detection of donor markers using STR-PCR on at least two occasions. 10 Both acute and chronic GVHD (cGVHD) were diagnosed and graded according to previously published criteria. 11, 12 Abbreviations: ATG = antithymocyte globulin; Flu = fludarabine; HSCT = hematopoietic SCT; MMF = mycophenolate mofetil.
Statistical analysis
All of the patients were followed up until 31 May 2014. The Kaplan-Meier method was used to estimate the probabilities of the OS and leukemia-free survival. Survival time was calculated from the second HSCT until death or until the last follow-up, independent of the need for further HSCT. GVHD, TRM and relapse were estimated using cumulative incidence curves to accommodate competing risks. 13 Most analyses were performed with SPSS 16.0 (SPSS Inc.,Chicago, IL, USA), and the cumulative incidence of GVHD, TRM and relapse were performed with R statistical software (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS

Engraftment
Fourteen patients achieved sustained engraftment with complete donor chimerism by day 30 following the second transplantation. Neutrophil and plt engraftment occurred in 14 (82.4%) and 13 (76.4%) patients, respectively. The median times to neutrophil recovery and plt recovery were 12 days (range, 11-15 days) and 17 days (range, 11-117 days), respectively. Three patients did not achieve neutrophil recovery after the second transplantation. Two of the patients died of severe infection on day 7 and 13 after the second transplantation. The other patient received a third transplantation but still did not engraft and ultimately died of multiple system organ failure. GVHD Among 14 evaluable cases, aGVHD was observed in 6 patients (52%) at a median time of 19 days (range, 15-30 days). Overall, three patients displayed grade II acute GVHD, and three patients presented grade IV acute GVHD (aGVHD). The cumulative incidences of grade II-IV and grade III-IV aGVHD were 35.3% (95% CI, 32.5-38.1%) and 17.6% (95% CI, 15.9-19.4%), respectively ( Figure 1) . cGVHD was observed in 5 of 12 evaluable patients, and the cumulative incidence of cGVHD was 29.4% (95% CI, 26.8-32.1%). A total of four patients experienced a limited form of cGVHD, and only one patient experienced an extensive form of cGVHD. Complete resolution of cGVHD with the discontinuation of any immunosuppressive therapy was observed in three patients with the limited form, whereas the other patient died of uncontrolled jaundice and liver failure. The patient with the extensive form of cGVHD continued to receive immunosuppressive therapy at the time of the analysis.
Toxicity of preparative regimens and infection Except for two patients who died of severe pulmonary infections before engraftment, the preparative regimens were well tolerated in the other patients. Hemorrhagic cystitis occurred in two patients before engraftment. Bloodstream infections occurred in another two patients and were well controlled. No severe organ dysfunction was observed in all patients during the preparative period. After neutrophil engraftment, three patients were clinically diagnosed with invasive fungal infections. Six patients developed CMV reactivation without symptoms of CMV disease. Two patients developed herpes zoster 3 months after the second transplantation. Only one patient developed EBV reactivation and no posttransplant lymphoproliferative disorder occurred.
TRM and cause of death A total of seven transplantation-related deaths occurred at a median time of 59 days (range, 7-659 days) after the second transplantation. The cumulative incidence of TRM 180days after the second transplantation was 29.4% (95% CI, 26.8-32.0%). The causes of death included severe pulmonary infections (n = 3), severe aGVHD combined with severe infection or multiple system organ failure (n = 2), cGVHD combined with liver failure (n = 1) and CNS complications (n = 1).
Survival
The median follow-up period for surviving patients after the second transplantation was 43 months (range, 13.5-99 months). Currently, 10 of 17 patients are alive. The 1-year OS and leukemiafree survival rate was 64.7%. The probability of 5-year OS and leukemia-free survival was 57.5% in all patients and 50% in highrisk patients (Figure 2 ).
DISCUSSION
Given the emergent condition of the patients, prospective controlled trials of salvage transplantation following by CBT are difficult. The available data on the outcomes after salvage transplantation to treat pGF are also limited; the optimal stem cell source, preparative regimen and time for salvage transplantation have not been established.
Generally, patients who received CBT almost always lack both matched-related and unrelated donors during the clinically relevant period. Secondary CBT as a salvage therapy after GF was commonly used, 11, 12, 14 but this approach is limited by a high incidence of infection and TRM owing to slow neutrophil recovery. The OS after transplantation is only 30-40%. Recently, some retrospective studies have indicated that haploidentical Figure 2 . Probability of OS. The 5-year OS for all patients and highrisk patients was 57.5% and 50%, respectively (P = 0.60).
transplantation as a salvage therapy for GF was superior to CBT. 15, 16 In a retrospective study by Kato, salvage HSCT from matched or one-Ag-mismatched-related donors (rMM01) provided superior OS compared with that from two-or three-Agsmismatched-related donors (rMM23) or CBT. Also, CBT showed a trend toward a slightly lower engraftment rate and late engraftment achievement compared with rMM01 or rMM23. 15 Although 16 of the 17 patients in our study received salvage HSCT from rMM2-3, results indicated that the 1-year OS and probability of 5-year OS were 64.7% and 57.5%, respectively. Better survival together with higher engraftment rate and shorter interval to neutrophil and plt recovery were achieved than previous studies salvaged with CBT. 11, 12, 14 New methods to improve the prognosis of haploidentical HSCT are currently under investigation. Many researchers focused on unmanipulated or T-cell-depleted haploidentical HSCT, which have both been reported to be available protocols. [7] [8] [9] [10] Several previous studies have confirmed that a low number of CD34 cells in grafts was associated with slower engraftment, particularly plt recovery. 17, 18 In addition, antithymocyte globulin is often accompanied by delayed immune reconstitution and severe infections, especially viral disease. 7 To overcome these problems, G-CSFmobilized BM combined with PB grafts were used in our study in order to get high-dose stem cell. 7 However, unmanipulated G-PB or G-BM alone from haploidentical donors were also recently reported to be promising protocols for allo-HSCT. 10, 19 Further randomized clinical studies are needed to identify the best choice of allograft.
High-risk patients accounted for as many as 58.8% (10/17) of the patients in this study, but none of the patients experienced relapse during follow-up. This finding can potentially be attributed to the fact that unmanipulated haploidentical transplantation may partly preserve the GVL effect. In addition, the two consecutive transplantation preparative regimens may also have an important role. Considering that the negative effect of the drug on neutrophil recovery and mucosal toxicity coexists with a susceptibility to infection, none of the patients received MTX as a GVHD prophylaxis, which was commonly used in the majority of other haploidentical HSCT protocols. However, the present data indicated that the incidences of aGVHD and cGVHD were not high in our patients. Although the number of patients in our study is too small to draw any conclusions, salvage haploidentical transplantations without in vitro T-cell depletion may be a promising protocol for pGF after CBT.
The cumulative organ toxicity caused by sequential preparative regimens is associated with considerable mortality. The ideal preparative regimen for the salvage HSCT would not only permit donor cell engraftment but also minimize regimen-related toxicities. Several studies have demonstrated that nonmyeloablative conditioning with fludarabine and low-dose TBI of HSCT can promote successful engraftment and long-term survival. 20, 21 A few reports also demonstrate that some cases can achieve engraftment without any preparative regimen. 22, 23 Given that residual host immunity is the main cause of GF, many patients might eventually experience autologous recovery or relapse, it is generally accepted that most pGF cases require a second preconditioning treatment. Over the past decade, RIC regimens have been widely adopted by large registry-based studies with promising results. 24, 25 However, the experience for haploidentical transplantation with RIC regimens has been limited. Several other researches undergoing second unrelated donor transplantations after pGF represented the larger current data set and indicated the relative safety and effectiveness of a reducedintensity, but highly immunosuppressive, preparative regimen during salvage transplantation. [14] [15] [16] However, the optimal components of the conditioning remain undetermined. In many studies of RIC transplantation, fludarabine-based regimens combined with an alkylator show a significantly higher probability of engraftment compared with regimens that do not include an alkylator. 26, 27 To overcome the HLA barrier, low-dose TBI is also frequently added to the regimen. 27 As for the irradiation dose, 3-5 Gy of irradiation is sufficient for engraftment, whereas the addition of irradiation did not increase the probability of engraftment. 15 Our data showed that the reduced-intensity TBI/ fludarabine/CY preparative regimen had a powerful potential to enable successful donor engraftment with limited toxicity during salvage transplantation for pGF.
The decision to perform a second transplantation by day 42 post CBT is often too late for some patients to complete. If there is no possibility of engraftment or autologous recovery, the outlook for patients with pGF is often precarious owing to prolonged pancytopenia and toxicity of the first-conditioning regimen. Proceeding to a salvage transplantation as quickly as possible may help to improve the survival. But, radical intervention should be avoided in the state of slow engraftment. However, it is difficult to differentiate early GF following CBT from delayed engraftment. Generally, pGF is diagnosed if patients fail to achieve an ANC of 0.5 × 10 9 /L or more by days 28 after BMT or PBSCT and days 42 after CBT. However, after CBT, some patients may obtain slow engraftment or autologous recovery after 42 days. With the development of PCR amplification of STR polymorphisms, pGF and delayed engraftment after CBT can be identified more reliably and earlier than usual by assessment of chimerism. Chan et al. 14 reported that in none of the patients, a detection of o5% donor cells on day 28 post CBT demonstrated subsequent donor engraftment. A donor chimerism level of 65% on day +14 might serve as the best cutoff for predicting pGF after a single-unit CBT, with a sensitivity of 97% and a specificity of 80%. 28 Similar conclusions were drawn in our previous study on double-unit CBT. 29 There is no evidence that the detection of o 5% donor cells on day 28 post CBT will certainly result in GF. However, simply waiting is unwise given that this finding is associated with a high possibility of irreversible GF in most cases. Recent reports have also been made on salvage transplantation based on early chimerism results. 11 In our present study, the chimerism analysis of patients is conventionally performed using STR-PCR weekly during the first month after CBT. If there is an absence or loss of donor cells on day 28 following CBT, pGF is defined, then salvage transplant will be proceeded. The median interval from the failed transplantation to salvage transplantation was 38 days (range, 32-59 days) with a TRM of 29.4% by day 180, which was favorable in salvage transplantation. Infections remained the leading cause of death.
In conclusion, our experience demonstrates that unmanipulated haploidentical transplantation with G-PB and G-BM is feasible in the management of pGF following CBT. RIC preparative regimens can ensure the engraftment of a second transplantation with tolerable toxicity. Routine chimerism analysis during the first month after CBT may help to distinguish GF from delayed engraftment, allowing earlier salvage transplantation for more patients with a favorable OS. Otherwise, we cannot draw firm conclusions concerning salvage transplantation owing to the complicated factors of patients. Prospective studies with large cohorts are required to further improve the prognosis of pGF patients after CBT.
